Cagrilintida
Long-acting amylin analogue
Amylin analogue that reinforces satiety; studied alone and combined.
Back to technical sheets- Class
- Long-acting amylin analogue
- Also known as
- Investigational compound (often studied with semaglutide)
Mechanism of action
Long-acting amylin receptor agonist. Amylin, co-secreted with insulin, slows gastric emptying and increases satiety; its combination with a GLP-1 agonist is being investigated for a possible additive effect.
Evidence
In clinical research (phase 2/3), alone and in combination. Promising preliminary results pending confirmation. Not approved.
Studied uses
- Obesity (under study, alone or combined)
Safety considerations
- Gastrointestinal effects expected from the mechanism
- Long-term safety data still limited
- Not available for approved clinical use
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Presentation
- Polvo liofilizado en vial sellado
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.